Matthias Kretzler, M.D.
Minghui Zhao, M.D., Ph.D.
Patients with end stage renal disease (ESRD) require renal replacement therapy associated with high morbidity, mortality and cost both in China and the US. The majority of ESRD originates from glomerular disease.
The UMHS and PUHSC renal divisions are at the forefront of translational glomerular disease research in the US and China. The groups have joined force to address the most urgent unmet need in the field, which is early and accurate identification of patients at high risk to progress to ESRD for targeted treatments. The joint scientific expertise, unique resources (Biobanks established by both divisions host urine and plasma samples accumulated over years from patients with glomerular diseases, these samples are linked with longitudinal clinical data), and the deep trust-based intensive cooperation and exchanges (including faculty training, multiple visits, shared seminars etc.) position us strongly to meet this challenge.
Together, we strive to develop non-invasive molecular markers to allow early detection of patients at high risk for progression, and identify molecular pathways that bridge the genotype-phenotype gap to identify molecular mechanisms driving glomerular disease progression as targets for future interventional trials. Our pilot study currently supported by the discovery award generated and will continuously generate crucial data for publication and for new or competitive renewal of federal and industry funding opportunities. Moreover, JI renal program provides a valuable platform to exchange research inspiration and to nurture new collaborations on renal diseases between both sides. In 2014 we are excited to welcome multiple new projects and many new co-investigators joining the program. We strongly believe that our joint effort will ultimately contribute to improve patient care and reduce financial burden in both US and China.